Search

  • Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology

 

Article | 15-February-2021

Serologic problems associated with administration of intravenous immune globulin (IVIg)

antibodies, some of which may cause clinical complications. Anti-A and/or anti-B antibodies present in IVIg can cause immune-mediated hemolytic anemia in non–group O patients, a finding reported to be about 34 percent of patients receiving IVIg in one prospective study.12 The hemolysis can occasionally be severe, even life-threatening.12–16 Some manufacturers have removed the majority of ABO isoagglutinins from IVIg by a chromatographic step in their processing, which may limit the risk of hemolytic

D.R. Branch

Immunohematology, Volume 35 , ISSUE 1, 13–15

Article | 16-February-2021

Quality improvement with platelet additive solution for safer out-of-group platelet transfusions

blood volume during transfusion. If the recipient is a secretor (80% of the population), the soluble A or B blood group substances in the recipient’s plasma can neutralize some anti-A or anti-B isoagglutinins in the donor’s plasma.12,13 This protection becomes ineffective, however, when the recipient is not a secretor or large amounts of anti-A and anti-B are involved.14 In the situation described, a single platelet component with a high isoagglutinin titer can be harmful,8,15–22 and even fatal,8,22

M. Tynuv, W.A. Flegel

Immunohematology, Volume 35 , ISSUE 3, 108–115

case-report | 25-June-2021

Neonatal testing leading to the identification of Bh (para-Bombay) phenotype in the mother: case report with review of the literature

per departmental standard protocol. The direct antiglobulin test (DAT) of the baby (Fig. 1A) as well as the mother’s ABO grouping were obtained (Table 1). The mother’s ABO grouping showed an unexpected reaction in the pooled O RBC suspension on serum testing, which led us to suspect a group 4 discrepancy (defined as an unexpected reaction in pooled RBCs because of ABO isoagglutinins or unexpected non-ABO alloantibodies),3 and hence anti-H lectin (Tulip Diagnostics, Goa, India) as well as indirect

G. Mohan, A. Vaidya, S. Shastry

Immunohematology, Volume 37 , ISSUE 2, 59–63

No Record Found..
Page Actions